Top 10 US Specialty Pharmacies Shaping Access 2026
Three PBM-owned pharmacies control two-thirds of specialty drug dispensing revenue — here’s the full landscape access teams need to navigate.
Total prescription dispensing revenue across US retail, mail, long-term care, and specialty pharmacies reached $751 billion in 2025, up 10% year-over-year, with GLP-1 drugs driving roughly 60% of that growth. But specialty dispensing itself remains highly concentrated: the three largest specialty pharmacies, each owned by a vertically integrated PBM, accounted for two-thirds of total specialty prescription revenue. Here’s the full landscape shaping patient access in 2026.
1. CVS Specialty (CVS Caremark)
One of the three PBM-owned specialty pharmacy giants controlling the majority of specialty dispensing revenue, offering integrated access across CVS Health’s broader pharmacy and PBM network.
2. Accredo (Cigna / Express Scripts)
Cigna’s specialty pharmacy arm, operating as part of the Express Scripts PBM network and representing one of the three dominant specialty dispensing organizations nationally.
3. Optum Specialty Pharmacy (UnitedHealth)
UnitedHealth’s specialty pharmacy operation, integrated with Optum Rx’s PBM infrastructure, completing the trio of vertically integrated giants that together dominate specialty drug dispensing.
4. CarelonRx Specialty Pharmacy
Offers national limited-distribution-drug access, 340B support, and speed-to-therapy positioning specifically built for complex specialty therapies requiring rapid patient onboarding.
5. Walgreens Specialty Pharmacy (with Hub Solutions)
A PBM-neutral national specialty pharmacy offering broad community access, 265+ limited-distribution-drug products, and Walgreens’ manufacturer-facing Hub Solutions platform.
6. Independent National Specialty Pharmacies
A category of PBM-independent operators combining high-touch patient access support, digital workflows, and manufacturer-facing visibility tools — increasingly relevant as manufacturers seek dispensing partners outside the PBM-owned giants.
7. Health System-Affiliated Specialty Pharmacies
The fastest-growing segment in the specialty pharmacy market, expanding rapidly from a small base as hospitals and health systems build in-house specialty dispensing capability tied to their own patient populations.
8. Independent Community Specialty Pharmacies
Smaller, locally-focused specialty operators gaining ground as manufacturers and patients seek alternatives to the concentrated PBM-owned dispensing model.
9. Walmart Health Specialty Services
A newer entrant leveraging Walmart’s retail scale and emerging telepharmacy and medication delivery capabilities to compete in specialty dispensing.
10. Amazon Pharmacy (Specialty)
A digital-first new entrant applying Amazon’s logistics and technology infrastructure to specialty drug delivery, part of a broader wave of non-traditional players reshaping how specialty medications reach patients.
What This Means for Access & Market Access Teams
Regulatory pressure on PBM-owned pharmacies is intensifying. The FTC secured a landmark settlement with Express Scripts in February 2026 and has pending lawsuits against Caremark and Optum, following findings that the Big 3 PBMs marked up specialty generics by thousands of percent — a dynamic manufacturers and access teams should factor into channel strategy.
Congress is forcing transparency into PBM economics. The February 2026 Consolidated Appropriations Act now requires 100% rebate pass-through and delinks PBM compensation from drug prices — a structural shift that will directly affect specialty pharmacy economics going forward.
Health systems are the segment to watch. With hospital- and health-system-affiliated specialty pharmacies as the fastest-growing category, manufacturers building channel strategy should evaluate direct relationships with health-system pharmacies, not just the traditional PBM-owned giants.
FAQ
How concentrated is the US specialty pharmacy market?
The three largest specialty pharmacies, all owned by vertically integrated PBMs (CVS, Cigna, and Optum), accounted for roughly two-thirds of total specialty drug dispensing revenue in 2025.
Why is the FTC investigating PBM-owned specialty pharmacies?
FTC staff reports found the three largest PBMs marked up specialty generic drugs by thousands of percent, generating over $7.3 billion in excess revenue between 2017 and 2022, prompting active enforcement action.
Which specialty pharmacy segment is growing fastest?
Hospital and health-system-affiliated specialty pharmacies are the fastest-growing category, as providers build in-house dispensing capability tied to their own patient populations.
Sources
- Drug Channels, The Top 15 Specialty Pharmacies of 2025
- Drug Channels, The Top 15 U.S. Pharmacies of 2025
- Drug Channels, The 340B Contract Pharmacy Market in 2026
- IntuitionLabs, US Specialty Pharmacies: A Guide to Mail-Order Providers
- Rx Almanac, Best Specialty Pharmacies for Pharma Manufacturers 2026
- Trillium Health, 2026 Specialty Pharmacy Market Report